Table 1 Baseline characteristics in HRT+ and HRT− cases
From: Hormone replacement therapy after surgery for stage 1 or 2 cutaneous melanoma
HRT+ | HRT− | ||
|---|---|---|---|
n (%) | n (%) | P-value | |
Ulceration | |||
Yes | 5 (6.2) | 21 (17.8) | 0.017* |
Patients with tumours <1 mm thick | 42 (50.6) | 58 (47.2) | 0.627* |
Patients with | |||
Superficial spreading melanoma | 60 (73.2) | 84 (69.4) | 0.846* |
Nodular/polypoid melanoma | 15 (18.3) | 25 (20.7) | |
Lentigo maligna melanoma | 4 (4.9) | 4 (4.3) | |
Acral/mucosal melanoma | 1 (1.2) | 2 (1.7) | |
Other and unspecified melanoma | 2 (2.4) | 6 (5.0) | |
Patients with lesions on | |||
Limbs | 59 (72.0) | 79 (65.3) | 0.602* |
Hands and feet | 3 (3.7) | 6 (5.0) | |
Other body parts | 20 (24.4) | 36 (29.8) | |
Deprivation category | |||
1 and 2 | 26 (31.7) | 32 (26.5) | 0.034* |
3, 4 and 5 | 50 (61.0) | 64 (52.9) | |
6 and 7 | 6 (7.3) | 25 (20.7) | |
Age | |||
Mean | 48.65 | 50.52 | 0.009** |
